| 10-year outcome of a randomized trial comparing neoadjuvant chemoradiotherapy and surgery with surgery alone for esophageal cancer (CROSS trial) B Eyck, J van Lanschot, M Hulshof, M van Berge Henegouwen, ... European Journal of Surgical Oncology 47 (2), e31, 2021 | 3 | 2021 |
| 10.04 Spatial transcriptomics identifies metabolic dysregulation as a key driver of T cell exclusion in esophageal adenocarcinoma J Sanders, EN Bos, N Hahn, I Nijman, HWM van Laarhoven, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 1), 2024 | | 2024 |
| 119: METASTASECTOMY OR STEREOTACTIC BODY RADIATION THERAPY FOR OLIGOMETASTATIC ESOPHAGOGASTRIC CANCER: A NATIONWIDE POPULATION-BASED COHORT STUDY T Kroese, N Jorritsma, N Haj Mohammad, S Mook, J Ruurda, ... Diseases of the Esophagus 35 (Supplement_1), doac015. 119, 2022 | | 2022 |
| 1222P Predictiveness of Mandard score on recurrence patterns of esophageal adenocarcinoma after neoadjuvant therapy and surgery D Liu, SP Henckens, MC Kalff, MF Bijlsma, C Oyarce, S Gisbertz, ... Annals of Oncology 33, S1107, 2022 | | 2022 |
| 1260TiP The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: A randomized multi-center study in resectable HER2 overexpressing … D Blangé, M Hulshof, MI van Berge Henegouwen, B Mostert, ... Annals of Oncology 33, S1123-S1124, 2022 | 1 | 2022 |
| 1302P Gender differences in tumor characteristics, treatment allocation and survival in patients in a real-world non-metastatic pancreatic cancer cohort AM Gehrels, H Wilmink, AD Wagner, MG Besselink, R Verhoeven, ... Annals of Oncology 33, S1139, 2022 | | 2022 |
| 1426P Gender differences in treatment characteristics and outcomes of esophagogastric cancer surgery-Data from the Dutch upper-GI cancer audit MC Kalff, AD Wagner, RH Verhoeven, V Lemmens, HWM van Laarhoven, ... Annals of Oncology 31, S902, 2020 | | 2020 |
| 1449P Hospital volume and beyond first-line palliative systemic treatment administration in metastatic esophagogastric adenocarcinoma: A population-based study WPM Dijksterhuis, RH Verhoeven, M Pape, M Slingerland, ... Annals of Oncology 31, S911, 2020 | | 2020 |
| 1458P Real-world treatment patterns of unresectable advanced or synchronous metastatic esophageal squamous cell cancer in a Western population M Pape, PAJ Vissers, J de Vos-Geelen, M Hulshof, HWM van Laarhoven, ... Annals of Oncology 31, S914, 2020 | | 2020 |
| 1461P Sex differences in treatment and survival of patients with unresectable or metastatic esophagogastric cancer: A population-based study WPM Dijksterhuis, MC Kalff, RH Verhoeven, AD Wagner, V Lemmens, ... Annals of Oncology 31, S916, 2020 | | 2020 |
| 1465P A nationwide population-based study comparing treatment patterns and outcomes in synchronous versus metachronous metastatic esophageal and gastric adenocarcinoma M Pape, PAJ Vissers, D Bertwistle, L McDonald, HWM van Laarhoven, ... Annals of Oncology 31, S917, 2020 | | 2020 |
| 1473P Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort E Pijnappel, M Schuurman, AD Wagner, J De Vos-Geelen, ... Annals of Oncology 32, S1089, 2021 | | 2021 |
| 1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18. 2) in gastric and … F Lordick, J Chao, E Buxò, HWM van Laarhoven, CMR Lima, S Lorenzen, ... Annals of Oncology 31, S928-S929, 2020 | 16 | 2020 |
| 1526P First and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort E Pijnappel, WPM Dijksterhuis, L Van Der Geest, J De Vos-Geelen, ... Annals of Oncology 31, S939-S940, 2020 | 3 | 2020 |
| 1553P Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study B Doeve, D Geijsen, M van Berge Henegouwen, M van Mourik, RE Pouw, ... Annals of Oncology 34, S870-S871, 2023 | | 2023 |
| 1563P Tumor-intrinsic subtypes of esophageal adenocarcinoma associate cellular phenotypes with responses to therapy D Blangé, M Dings, A van der Zalm, M Lansbergen, M Verzaal, C Oyarce, ... Annals of Oncology 34, S874, 2023 | | 2023 |
| 1574P Trastuzumab deruxtecan versus ramucirumab and paclitaxel as second-line therapy for patients with her2-positive gastric or gastro-esophageal junction adenocarcinoma: A … RHA Verhoeven, S Kuijper, F Lordick, M Slingerland, A Qin, ... Annals of Oncology 34, S878, 2023 | | 2023 |
| 1575P Factors associated with uptake of adjuvant nivolumab in a nationwide esophageal cancer patient cohort RHA Verhoeven, NH Mohammad, P Vissers, D Bertwistle, P Singh, ... Annals of Oncology 34, S879, 2023 | | 2023 |
| 1589P Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin NAD Guchelaar, BJ Noordman, M Welten, M van Santen, MJ de Neijs, ... Annals of Oncology 34, S884, 2023 | | 2023 |
| 1594P End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands E Slotman, H Fransen, HWM van Laarhoven, ... Annals of Oncology 34, S886-S887, 2023 | | 2023 |
